Company news
Grace Therapeutics, Inc. (NASDAQ:GRCE) news
Grace Therapeutics, Inc. news releases on 6ix. Latest, Sep 3, 2026: Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment…
Press releases & updates
Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference
September 3, 2026
Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update
August 13, 2026
Grace Therapeutics Announces $10 Million Private Placement
August 3, 2026
Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration
July 28, 2026
Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
June 18, 2026
Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
April 23, 2026
Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026
April 14, 2026
Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences
March 19, 2026
Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
February 25, 2026
Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update
February 12, 2026
Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference
November 17, 2025
Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update
November 13, 2025
Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting
November 11, 2025
Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review
October 23, 2025
Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting
September 22, 2025
Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104
September 18, 2025
Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference
September 4, 2025
Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104
August 27, 2025
Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update
August 12, 2025
Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104
June 25, 2025
Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update
June 23, 2025
Grace Therapeutics to Participate in the 2025 BIO International Conference
June 13, 2025
Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104
April 9, 2025
Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
February 25, 2025
Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update
February 12, 2025
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
February 9, 2025
Grace Therapeutics to Exhibit at the American Society of Health-System Pharmacists Conference
December 3, 2024
Grace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business Update
November 12, 2024
Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024
October 29, 2024